Interesting - but misleading. Those are the side effects seen seen in the high daily doses seen in applications for cancer therapy, etc. - not the side effects seen in the weekly dosing (or once every two weeks) that is typically used in anti-aging applications.
Here are the side effects seen with Everolimus (RAD001, Novartis Afinitor) in the famous Mannick 2014 clinical trial (with elderly but healthy people, dosed weekly) where it was shown to improve aging immune systems in people.
Interestingly, they reported only 1 serious adverse event in the study:
Only one severe adverse event was assessed as related to RAD001: mouth ulcers in a subject treated with 20 mg weekly RAD001.
